Advertisement

Morbus Parkinson — Gehirnerkrankung oder Ganzkörpererkrankung?

  • H. Reichmann
  • T. Ziemssen
Conference paper
  • 68 Downloads

Zusammenfassung

Mit dem idiopathischen Parkinson-Syndrom wird neurologischer- und psychiatrischerseits bevorzugt eine Störung der zentralen Motorik assoziiert, die sich in den Kardinalsymptomen Ruhetremor, Bradykinese, rigorartige Tonuserhöhung und zum Teil posturale Instabilität äußert. Aus psychiatrischer Sicht sind darüber hinaus Komplikationen in ca. 10 bis 20% zu erwaähnen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aminoff MJ, Wilcox CS (1971) Assessment of autonomic function in patients with a Pakinsonian syndrome. Br Med J 4: 80–84PubMedCrossRefGoogle Scholar
  2. 2.
    Appenzeller O, Goss JE (1971) Autonomic deficits in Parkinson’s syndrome. Arch Neurol 24: 50–57PubMedCrossRefGoogle Scholar
  3. 3.
    Bannister R, Oppenheimer DR (1972) Degeberative diseases of the nervous system associated with autonomic failure. Brain 95: 457–474PubMedCrossRefGoogle Scholar
  4. 4.
    Benecke R, Striimper P, Weiss H (1993) Electron transfer complexes I and IV of platelets are abnormal in Parkinson’s disease but normal in Parkinson-plus syndromes. Brain 116: 1451–1463PubMedCrossRefGoogle Scholar
  5. 5.
    Bethlem J, Den Hartog Jager WA (1960) Zje incidence and characteristics of Lewy bodies on idiopathic paralysis agitans (Parkinson’s disease). J Neurol. Neurosurg Psychiatry 23: 74–80PubMedCrossRefGoogle Scholar
  6. 6.
    Beyer MK, Herlofson K, Arsland D, Larsen JP (2001) Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 103: 7–11PubMedCrossRefGoogle Scholar
  7. 7.
    Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH (1999) Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 53: 1020–1025PubMedCrossRefGoogle Scholar
  8. 8.
    Eady MJ (1963) Gastric secretion in parkinsonism. Australas Ann Med 12: 346–350Google Scholar
  9. 9.
    Eady MJ, Tyrer JH (1965) Alimentary disorder on parkinsonism. Australas Ann Med 14: 13–22Google Scholar
  10. 10.
    Edwards L, Quigley EMM, Hofman R, Pfeiffer TF (1993) Gastrointestinal symptoms in Parkinson Disease: 18-month follow-up study. Mov Disord 8: 83–86PubMedCrossRefGoogle Scholar
  11. 11.
    Elliot K, Côté LJ, Frewin DB, Downey JA (1974) Vascular responses in the hands of Parkinson’s disease patients. Neurology 24: 857–862CrossRefGoogle Scholar
  12. 12.
    Forno LS (1986) The Lewy body in Parkinson’s disease. Adv Neurol 45: 95–43Google Scholar
  13. 13.
    Goetz CG, Lutge W, Tanner CM (1986) Autonomic dysfunction in Parkinson’s disease. Neurology 36: 73–75PubMedCrossRefGoogle Scholar
  14. 14.
    Greenfield JG, Bosanquet FD (1953) The brain-stem lesions in parkinsonism. J Neurol Neurosurg Psychiatry 16: 213–226PubMedCrossRefGoogle Scholar
  15. 15.
    Gu M, Cooper JM, Taanman JM, Schapira AHV (1998) Mitochondrial DNA transmission of the mitochondrial defect in Parkinson’s disease. Ann Neurol 44: 177–186PubMedCrossRefGoogle Scholar
  16. 16.
    Hess CW, Enderli JB, Frohlich-Egli F, Ludin HP (1987) Neurogene Blasenfunktiönsstorungen beim Morbus Parkinson. Nervenarzt 58: 55–60PubMedGoogle Scholar
  17. 17.
    Hoehn MM, Yahr MD (1967) Parkinsonism. Onset, progression and mortality. Neurology 17: 427–442PubMedCrossRefGoogle Scholar
  18. 18.
    Indo T, Ando K (1982) Metclopramide-induced parkinsonism. Arch Neurol 39: 494–496PubMedCrossRefGoogle Scholar
  19. 19.
    Janetzky B, Hauck S, Youdim MB, Riederer P, Jellinger K, Pantucek F, Zochling R, Boissl KW, Reichmann H (1994) Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson’s disease. Neurosci Lett 169: 126–128PubMedCrossRefGoogle Scholar
  20. 20.
    Javoy-Agid F, Ruberg M, Pique L, Berzagna X et al. (1984) Biochemistry of the hypothalamus in Parkinson’s disease. Neurology 34: 672–675PubMedCrossRefGoogle Scholar
  21. 21.
    Jost WH (1999) Autonome Regulationsstorungen beim Parkinson-Syndrom. Shaker, AachenGoogle Scholar
  22. 22.
    Korczyn AD (1990) Autonomic nervous system disturbances in Parkinson’s disease. Adv Neurol 53: 463–468PubMedGoogle Scholar
  23. 23.
    Kuroiwa Y, Shimada Y, Toyokura Y (1983) Postural hypotension and low RR-interval variability in parkinsonism, spinocerebellar degeneration, and Shy-Drager syndrome. Neurology 33: 463–467PubMedCrossRefGoogle Scholar
  24. 24.
    Kuroiwa Y, Wada T, Tohgi H (1987) Measurement of blood pressure and heart-rate variation while resting supine and standing for the evaluation of autonomic dysfunction. J Neurol 235: 65–68PubMedCrossRefGoogle Scholar
  25. 25.
    Laroche M, Delisle MB, Aziza R, Lagarrigue J, Mazieres B (1995) Is camptocormia a primary muscular disease? Spine 20: 1011–1016PubMedCrossRefGoogle Scholar
  26. 26.
    Lees AJ, for the PDRG-UK (1995) Comparison of the therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Brit Med J 311: 1602–1607PubMedCrossRefGoogle Scholar
  27. 27.
    Lewy FH (1913) Zur pathologischen Anatomie der Paralysis agitans. Dtsch Z Nervenheik 50: 50–55Google Scholar
  28. 28.
    Malarkey WB, Cyrus J, Paulson GW (1974) Dissociation of growth hormone and prolactin secretion in Parkinson’s disease following chronic L-Dopa therapy. J Clin Endocrin Metab 39: 229–235CrossRefGoogle Scholar
  29. 29.
    Mano Y, Nakamuro T, Takayanagi T, Mayer RF (1994) Sweat function in Parkinson’s disease. J Neurol 241: 573–576PubMedCrossRefGoogle Scholar
  30. 30.
    Martignoni E, Pacchetti C, Godi L, Micieli G, Nappi G (1995) Autonomic disorders in Parkinson’s syndrome. J Neural Transm 45 Suppl: 11–19Google Scholar
  31. 31.
    Meco H, Pratesi L, Bonifati V (1991) Cardiovascular reflexes and autonomic dysfunction in Parkinson’s disease. J Neurol 238: 195–199PubMedCrossRefGoogle Scholar
  32. 32.
    Mesec A, Sega S, Kiauta T (1993) The influence of type, duration, severity and levodopa treatment of Parkinson’s disease on cardiovascular autonomic responses. Clin Autonom Res 3: 339–344CrossRefGoogle Scholar
  33. 33.
    Mosewich RK, Rajput AH, Shuaib A, Rozdilsky B, Ang L (1994) Pulmonary embolism: an under-recognized yet frequent cause of death in parkinsonism. Mov Disord 9: 350–352PubMedCrossRefGoogle Scholar
  34. 34.
    Parkinson J (1817) An essay in the shaking palsy. Sherwood, Neely, and Jones, LondonGoogle Scholar
  35. 35.
    Piha SJ, Rinne JO, Rinne UK, Seppänen A (1988) Autonomic dysfunction in recent onset and advanced Parkinson’s disease. Clin Neurol Neurosurg 90: 221–226PubMedCrossRefGoogle Scholar
  36. 36.
    Przuntek H, Welzel D, Gerlach M, Bliimner E, Danielczyk W, Kaiser HJ, Kraus PH, Letzel H, Riederer P, Überla K (1996) Early institution of bromocriptine in Parkinson’s disease inhibits the emergence of levodopa associated motor side effects. Long-term results of the PRADO study. J Neural Transm 103: 699–715PubMedCrossRefGoogle Scholar
  37. 37.
    Rajput AH, Rozdilsky B (1976) Dysautonomia in parkinsonism: a clinicopathological study. J Neurol Neurosurg Psychiatry 39: 1092–1100PubMedCrossRefGoogle Scholar
  38. 38.
    Reichmann H, Janetzky B, Bischof F, Seibel P, Schöls L, Kuhn W, Przuntek H (1994) Unaltered respiratory chain enzyme activity and mitochondrial DNA in skeletal muscle from patients with idiopathic Parkinson’s syndrome. Eur Neurol 34: 263–267PubMedCrossRefGoogle Scholar
  39. 39.
    Sabate M, Gonzalez I, Ruperez F, Rodriguez M (1996) Obstructive and restricitive pulmonary dysfunctions in Parkinson’s disease. J Neurol Sci 138: 114–119PubMedCrossRefGoogle Scholar
  40. 40.
    Sato Y, Kaji M, Tsuru T, Oizumi K (2001) Risk factors for hip fracture among elderly patients with Parkinson’s disease. J Neurol Sci 182: 89–93PubMedCrossRefGoogle Scholar
  41. 41.
    Shoffner JM, Watts RI, Juncos JL, Torroni A, Wallace DC (1991) Mitochondrial oxidative phosphorylation defects in Parkinson’s disease. Ann Neurol 30: 332–339PubMedCrossRefGoogle Scholar
  42. 42.
    Taly AB, Muthane UB (1992) Involvement of peripheral nervous system in juvenile Parkinson’s disease. Acta Neurol Scand 85: 272–275PubMedCrossRefGoogle Scholar
  43. 43.
    Wakabayashi K, Takahashi S (1997) Neuropathology of the autonomic nervous system in Parkinson’s disease. Eur Neurol 38 Suppl 2: 2–7CrossRefGoogle Scholar
  44. 44.
    Wakabayashi K, Takahashi S, Ohama E, Takeda S, Ikuta F (1993) Lewy bodies in the visceral nervous system in Parkinson’s disease. Adv Neurol 60: 609–612PubMedGoogle Scholar
  45. 45.
    Watkins P (2000) COMT inhibitors and liver toxicity. Neurology 55: S51–52PubMedCrossRefGoogle Scholar
  46. 46.
    Wermuth L, Stenager E (1995) Sexual problems in young patients with Parkinson’s disease. Acta Neurol Scand 91: 453–455PubMedCrossRefGoogle Scholar
  47. 47.
    Winkler AS, Marsden J, Parton M, Watkins PJ, Chauduri KR (2001) Erythropoietin deficiency and anaemia in multiple system atrophy. Mov Disord 16: 233–239PubMedCrossRefGoogle Scholar
  48. 48.
    Yoshita M (2000) Cardiac uptake of [123I]MIBG separates PD from multiple system atrophy. Neurology 54: 1977CrossRefGoogle Scholar
  49. 49.
    Ziemssen T, Süß M, Reichmann (2001) Funktionsdiagnostik des autonomen Nervensystems - eine interdisziplinäre Herausforderung. Sächsisches Ärzteblatt 8: 363–379Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • H. Reichmann
  • T. Ziemssen

There are no affiliations available

Personalised recommendations